Genprex Partners with University of Pittsburgh for Groundbreaking Diabetes Gene Therapy Research in Type 1 and Type 2 Diabetes

AUSTIN, Texas, May 7, 2025 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX) is excited to announce a new research partnership with the University of Pittsburgh to investigate GPX-002, a gene therapy designed for Type 1 (T1D) and Type 2 diabetes (T2D). This follows a successful two-year study that revealed promising results in reducing insulin needs and improving glucose tolerance in animal models.

Ryan Confer, CEO of Genprex, expressed enthusiasm about the ongoing research. “Our studies of GPX-002 are showing significant potential in transforming diabetes treatment,” he said. The new agreement will support further preclinical studies, examining how this therapy can be effective in managing both types of diabetes.

Initial studies with GPX-002 have shown considerable promise. In T1D models, the therapy not only decreased insulin requirements but also raised c-peptide levels and enhanced glucose tolerance. These findings suggest that GPX-002 could provide a groundbreaking approach to diabetes management, particularly given that conventional treatments often come with challenges and limitations.

Mark Berger, MD, the Chief Medical Officer at Genprex, noted, “We’re optimistic about expanding GPX-002 to include T2D, as our preclinical data supports this change.” The therapy uses an adeno-associated virus (AAV) to deliver key genes directly into the pancreas. This method aims to invigorate the insulin-producing cells, offering a fresh avenue for treatment where few options exist.

Diabetes is a growing concern in the U.S. According to the CDC, around 38.4 million Americans—approximately 11.6% of the population—live with diabetes. As the population ages and lifestyles change, these numbers are expected to rise rapidly. In fact, a recent study reported that globally, the number of adults living with diabetes could hit 643 million by 2030, highlighting an urgent need for new treatments.

Both T1D and T2D present unique challenges. T1D often results from autoimmune issues where the body attacks insulin-producing cells, while T2D is linked to insulin resistance and beta-cell exhaustion. GPX-002 aims to tackle these conditions in innovative ways, offering hope where traditional therapies may fall short.

Genprex remains committed to advancing gene therapy as a viable treatment option for diabetes. The collaboration with the University of Pittsburgh is a step forward in exploring these revolutionary therapies. If clinical trials prove successful, they could change the landscape of diabetes management.

For more details on the ongoing research and its implications, you can visit Genprex’s official website: [Genprex, Inc.](https://www.genprex.com).

Source link